Form 4 for CTNM Contineum Therapeutics, Inc.
Accepted 2026-02-26 00:00:00 ET · period of report 2026-02-24 · accession 0001437749-26-005892 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-26 | 2026-02-24+ | CTNM | Stengone Carmine N. | CEO, Pres, Dir | M - OptEx | $1.26 | +7,100 | 17.7K | +67% | +$8,946 |
| DM | 2026-02-26 | 2026-02-24+ | CTNM | Stengone Carmine N. | CEO, Pres, Dir | S - Sale+OE | $16.02 | -7,100 | 15.0K | -32% | -$113.7K |
| DM | 2026-02-26 | 2026-02-24+ | CTNM | Stengone Carmine N. | CEO, Pres, Dir | M - OptEx | $0.00 | -7,100 | 120.9K | -6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-02-24 | M | A | 4,400 | $1.26 | 19,354 | D | — | — | |
| 2 | Common | Class A Common Stock | 2026-02-24 | S | D | 4,400 | $16.02 | 14,954 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| 3 | Common | Class A Common Stock | 2026-02-25 | M | A | 2,700 | $1.26 | 17,654 | D | — | — | |
| 4 | Common | Class A Common Stock | 2026-02-25 | S | D | 2,700 | $16.02 | 14,954 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.05, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| 5 | Derivative | Stock Option (right to buy) | 2026-02-24 | M | D | 4,400 | $0.00 | 123,617 | D | $1.26 · — to 2028-11-13 | 4,400 Class A Common Stock | (F4) The stock options are fully vested and exercisable. |
| 6 | Derivative | Stock Option (right to buy) | 2026-02-25 | M | D | 2,700 | $0.00 | 120,917 | D | $1.26 · — to 2028-11-13 | 2,700 Class A Common Stock | (F4) The stock options are fully vested and exercisable. |